The independent residency in vascular and endovascular surgery of the Vanderbilt University Medical Center is a two-year ACGME-approved fellowship preparing surgeons for a career in vascular surgery. Trainees receive extensive training in all aspects of care for vascular disease, including medical management, endovascular therapy, and open operations. The fellowship is based on a distinctive two-year curriculum, with the first year focused on gaining endovascular skills, achieving expertise in noninvasive testing, and performing a wide range of open operations. The second year is an intensive clinical experience in complex endovascular and open procedures.
During the two years, fellows receive extensive training in endovascular therapy, including diagnostic angiography, angioplasty and stenting, atherectomy devices, and endovascular grafts to treat aneurysmal disease of the thoracic and abdominal aorta. Graduates also receive training in advanced open and hybrid- procedures such as thoracoabdominal aneurysm repair and debranching procedures. By the end of the second year, trainees have typically performed approximately 1,500 operations covering the full range of pathology in arterial, venous, and lymphatic disease.
Faculty members in the Division of Vascular Surgery oversee a wide spectrum of research programs, and fellows are encouraged to participate in basic or clinical research. During the first year, fellows are expected to develop a patient safety project, and many of these have evolved into clinical research studies leading to publication in peer review journals. Fellows may also participate in ongoing basic science projects in funded research laboratories.
Vanderbilt University Medical Center is an ideal place to train. Vanderbilt's winning qualities include our community and regional location, nationally highly ranked medical and surgical programs, high quality faculty and funded research. Vanderbilt's hometown Nashville is a vibrant, energetic community that embraces innovation and invention, of which Vanderbilt is a major part.
Vanderbilts Independent Vascular Surgery Residency Program is approved by the Surgical Residency Review Committee (S-RRC) to graduate one resident annually. In addition to two fellows, the Division of Vascular Surgery includes five full-time vascular surgeons, one nurse practitioner, and two nurse clinical specialists. Faculty in vascular surgery have individual interests and expertise that provide patient care for all vascular diseases and conditions. These include peripheral arterial disease, carotid disease, visceral and renovascular disorders, as well as aneurysm disease of the thorax, abdomen, and extremities. Minimally invasive techniques are routinely applied in the management of peripheral interventions as well as the management of aneurysms.
Vanderbilt University Medical Center boasts 1,105 total beds, including 834 in Vanderbilt Hospital and 271 in the Monroe-Carell Jr. Childrens Hospital. Vanderbilt's 56 adult and 16 pediatric ORs perform over 51,000 surgeries annually. The Division of Vascular Surgery is part of the Vanderbilt Heart and Vascular Institute. This allows consolidation of clinical care for patients with cardiovascular disease in a single location with all specialists involved at hand to maximize both patient care and educational experiences. Each year, the Division of Vascular Surgery provides comprehensive care to approximately 6,000 patients who suffer from vascular diseases and conditions. Division Chief Thomas Naslund, M.D., directs an IAC-accredited noninvasive vascular laboratory that performs 5,000 vascular studies on an annual basis and is supported by five full- or part-time vascular technologists (RVTs).
Under the direction of Colleen Brophy, M.D., the division has a robust basic science research program. Dr. Brophys research has centered on enhancing patency of vascular bypass grafts. Among other discoveries, Dr. Brophys laboratory has identified a protein that is felt to be involved with relaxation of smooth muscle associated with vascular bypass grafts and other smooth muscle tissue. These efforts are funded through NIH and the Veterans Administration and are being expanded through bioengineering collaborative efforts to develop therapeutic agents in the treatment of fibrosis, inflammatory disorders, and epithelial cancers.
Christine Deyholos, M.D.
Associate Program Director
Assistant Professor of Surgery